Abbott Laboratories

NYSE:ABT Rapporto sulle azioni

Cap. di mercato: US$202.6b

Abbott Laboratories Gestione

Gestione criteri di controllo 3/4

Abbott Laboratories Il CEO è Robert Ford, nominato in Oct2018, e ha un mandato di 6.08 anni. la retribuzione annua totale è $ 23.27M, composta da 6.4% di stipendio e 93.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.024% delle azioni della società, per un valore di $ 48.76M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.8 anni e 5.8 anni.

Informazioni chiave

Robert Ford

Amministratore delegato

US$23.3m

Compenso totale

Percentuale dello stipendio del CEO6.4%
Mandato del CEO6.1yrs
Proprietà del CEO0.02%
Durata media del management5.8yrs
Durata media del Consiglio di amministrazione5.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist

Oct 31
Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist

Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation

Oct 21

Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event

Oct 14

Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?

Oct 11
Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?

Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price

Sep 27
Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price

Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change

Sep 11

A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Aug 16
A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Driving Value By Scaling Innovations

Aug 13

Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors

Aug 05

Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough

Jul 13

These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well

Jul 01
These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well

Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price

Jun 18
Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price

Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)

Jun 04
Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Why I Agree With Wall Street On This One

Jun 04

Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock

May 18

Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings

Apr 17

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Apr 15
Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now

Mar 21

Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger

Mar 19
Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger

Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly

Mar 06
Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly

Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024

Feb 27

Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon

Feb 08
Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon

The King Is Back: Abbott Laboratories' Path To >11% Annual Returns

Jan 29

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Jan 26
The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Robert Ford rispetto agli utili di Abbott Laboratories?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

US$6b

Jun 30 2024n/an/a

US$6b

Mar 31 2024n/an/a

US$6b

Dec 31 2023US$23mUS$2m

US$6b

Sep 30 2023n/an/a

US$5b

Jun 30 2023n/an/a

US$5b

Mar 31 2023n/an/a

US$6b

Dec 31 2022US$22mUS$2m

US$7b

Sep 30 2022n/an/a

US$8b

Jun 30 2022n/an/a

US$9b

Mar 31 2022n/an/a

US$8b

Dec 31 2021US$25mUS$1m

US$7b

Sep 30 2021n/an/a

US$7b

Jun 30 2021n/an/a

US$6b

Mar 31 2021n/an/a

US$6b

Dec 31 2020US$20mUS$1m

US$4b

Sep 30 2020n/an/a

US$3b

Jun 30 2020n/an/a

US$3b

Mar 31 2020n/an/a

US$4b

Dec 31 2019US$12mUS$1m

US$4b

Sep 30 2019n/an/a

US$3b

Jun 30 2019n/an/a

US$3b

Mar 31 2019n/an/a

US$3b

Dec 31 2018US$8mUS$784k

US$2b

Sep 30 2018n/an/a

US$802m

Jun 30 2018n/an/a

US$812m

Mar 31 2018n/an/a

US$365m

Dec 31 2017US$5mUS$675k

US$344m

Compensazione vs Mercato: La retribuzione totale di Robert ($USD 23.27M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 12.67M ).

Compensazione vs guadagni: La retribuzione di Robert è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Robert Ford (50 yo)

6.1yrs

Mandato

US$23,268,171

Compensazione

Mr. Robert B. Ford has been the Chief Executive Officer of Abbott Laboratories since March 31, 2020 and also serves as its Chairman of the Board since December 10, 2021. He has been President at Abbott Lab...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Robert Ford
Chairman of the Board6.1yrsUS$23.27m0.024%
$ 48.8m
Philip Boudreau
CFO & Executive VP of Finance1.2yrsUS$3.32m0.0023%
$ 4.6m
Hubert Allen
Executive VP11.8yrsUS$7.42m0.011%
$ 21.6m
Daniel Salvadori
Executive VP and Group President of Established Pharmaceuticals & Nutritional Products10.2yrsUS$5.93m0.0073%
$ 14.7m
Lisa Earnhardt
Executive VP & Group President of Medical Devices5.8yrsUS$5.50m0.0035%
$ 7.2m
Sabina Ewing
Senior VP of Business & Technology Services and Chief Information Officerless than a yearNessun datoNessun dato
Michael Comilla
Vice President of Investor Relations.no dataNessun datoNessun dato
Erica Battaglia
VP and Chief Ethics & Compliance Officerno dataNessun datoNessun dato
Melissa Brotz
Vice President of Public Affairs & Corporate Marketingno dataNessun datoNessun dato
Christopher Scoggins
Senior Vice President of Commercial Operations1.8yrsNessun datoNessun dato
Mary Moreland
Executive Vice President of Human Resources5.3yrsNessun dato0.0059%
$ 12.0m
Jared Watkin
Executive Vice President of Diabetes Care9.4yrsNessun dato0.0042%
$ 8.4m

5.8yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di ABT è esperto e expertise (durata media dell'incarico 5.8 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Robert Ford
Chairman of the Board5yrsUS$23.27m0.024%
$ 48.8m
Daniel Starks
Independent Director7.8yrsUS$349.29k0.39%
$ 783.7m
John Stratton
Independent Director7.8yrsUS$341.96k0.00020%
$ 405.2k
Nancy McKinstry
Lead Independent Director12.9yrsUS$405.96k0.00027%
$ 547.0k
Michael Roman
Independent Director3.6yrsUS$337.96k0%
$ 0
Robert Alpern
Independent Director16.1yrsUS$441.44k0%
$ 0
Michael O'Grady
Independent Director1.6yrsUS$283.96k0%
$ 0
Michelle Kumbier
Independent Director6.4yrsUS$331.96k0.00018%
$ 364.7k
Sally Blount
Independent Director12.9yrsUS$362.60k0.00015%
$ 303.9k
Claire Babineaux-Fontenot
Independent Director2.2yrsUS$354.96k0%
$ 0
Darren McDew
Independent Director5.2yrsUS$331.19k0%
$ 0
Patricia Gonzalez
Independent Director3.3yrsUS$356.96k0%
$ 0

5.8yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ABT sono considerati esperti (durata media dell'incarico 5.8 anni).